university health network research report 2007

Welcome to the UHN Research Report 2007:

University Health Network is Canada's premier research hospital and an affiliate of the University of Toronto.

Our vision is to have global impact in biomedical and health care research.

UHN Research comprises three research institutes: Ontario Cancer Institute (including Advanced Medical DiscoveryInstitute and The Campbell Family Institute for Breast Cancer Research), at Princess Margaret Hospital; TorontoGeneral Research Institute, at Toronto General Hospital; and Krembil Research Institute, at Toronto Western Hospital.

This year our Research Report focuses on our successes in regenerative medicine. Regenerative medicine is acompelling field of research that promises new treatments for some of the most devastating human diseases. And UHNis leading the way.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/

1 of 1 4/21/2016 10:03 AM

UHN Transforms Regenerative Medicine

UHN’s purpose statement is, “We are a caring, creative andaccountable academic hospital, transforming health care for ourpatients, our community and the world”.

One type of transformative health care is regenerative medicine. Itoffers the promise of dramatically changing current medicalpractice and improving the lives of millions worldwide. UHNinvestigators, working with UHN clinicians, staff and trainees, areat the forefront of this new field.

Our regenerative medicine initiatives are one reason why UHN isa leader among research hospitals. Please read on to learn more.

Dr. Robert S. BellPresident and CEOUniversity Health Network

UHN Invests in New Ways of Healing

This past year has been a year of tremendous growth anddevelopment of the UHN research enterprise.

We've welcomed new OCI Director Dr. Ben Neel to our leadershipteam. We've received $49M in new infrastructure funding towardsthe creation of five new research centres across UHN. We'veseen additional institutions join our new Shanghai-TorontoInstitute for Health Research.

But a major focus this year has been the dramatic expansion ofour regenerative medicine program.

Regenerative medicine seeks to utilize the body's own cells indeveloping treatments for disease. A field which is in early stages,it has the potential to transform the lives of millions afflicted bynumerous diseases, such as stroke, diabetes, rheumatoidarthritis, spinal cord injury, and Parkinson's disease.

Regenerative medicine constitutes one of UHN's research priorityplatforms and has been the focus of substantial investment ofresources.

2006/07 saw several developments that further signified UHN'scommitment to this area.

The McEwen Centre for Regenerative Medicine, generouslyfunded by donors Rob and Cheryl McEwen, was launched lastOctober, becoming UHN's official hub for regenerative medicinediscoveries. Director Gordon Keller has overseen the opening ofthe centre, providing strong intellectual leadership in the field andcreating a diverse, multi-institutional research team.

Two large RM initiatives—a cancer stem cell centre and a

UHN Research—International ResearchAdvisory Board

Philip Branton (Chair), PhD, FRSC / MSRCScientific DirectorCIHR Institute of Cancer Research

Dr. Robert S. Bell, President and CEO, UHN

Dr. Christopher J. Paige, VP, Research, UHN

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/welcome.php

1 of 2 4/21/2016 10:05 AM

regenerative medicine program spanning cell therapy, genetherapy and tissue engineering—won nearly $23 million ingovernment funding.

Regenerative medicine offers the promise of transforming currentmedical practice, and in these new initiatives UHN researchersare working to bring this dream to fruition. Together—UHNresearchers, support staff, our Foundations and our colleaguesfrom the University of Toronto and other Toronto Academic HealthScience Network institutions—we are generating the innovationsthat will make this dream a reality.

Dr. Christopher J. PaigeVice-President, ResearchUniversity Health Network

Victor Dzau, MDPresident & CEO, Duke University Health SystemThe Chancellor for Health AffairsDuke University Medical Center

Ralph Steinman, MDHenry G. Kunkel Professor and Senior PhysicianRockefeller University

Hans Wigzell, MD, PhDProfessor, Microbiology and Tumor BiologyCenterKarolinska Institute

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/welcome.php

2 of 2 4/21/2016 10:05 AM

Research Space

Publications

External ResearchFunding

737,000 sq ft

1,442

$223,799,000

Senior Scientists

Scientists

Affiliate Scientists

CRSC/CRU Members

Total Researchers

151

48

56

219

474

Fellows

Graduate Students

Total Trainees

Technical/Support Staff

493

374

867

1,289

OCI Scientists

Applied Molecular Oncology

Senior ScientistsAsa, SylviaBristow, RobertEzzat, ShereenGallie, BrendaHedley, DavidHill, RichardKamel-Reid,Suzanne

Liu, Fei-FeiMoore, MalcolmSquire, JeremyTannock, IanTsao, Ming-Sound

ScientistsDone, SusanMartin, Lisa

Trudel, SuzanneLiu, Geoffrey

Biophysics & Bioimaging

Senior ScientistsChakrabartty,AvijitHunt, JohnJaffray, DavidSherar, Michael

Vitkin, AlexWilson, BrianZheng, Gang

ScientistsLilge, Lothar Siewerdsen,

Jeffrey

Cancer Genomics & Proteomics

Senior ScientistsArrowsmith,CherylGariépy, JeanPai, Emil

Penn, LindaPrivé, GilbertRose, David

ScientistsKislinger, ThomasRaught, Brian

Schimmer, AaronTillier, Elisabeth

Affiliate ScientistBradley, Grace

Epidemiology, Statistics &Behaviour

Senior ScientistsBoyd, NormanCunningham,Alastair

Minkin, SalomonTill, JamesTritchler, David

Affiliate ScientistRitvo, Paul

Psychosocial Oncology & PalliativeCare

TGRI Scientists

Behavioural Sciences & Health

Senior ScientistsFlint, AlastairKaplan, AllanKatz, Joel

Olmsted, MarionRodin, GaryStewart, Donna

ScientistsCarter, JacquelineJones, Jennifer

Nolan, RobertRegehr, Glenn

AffiliateScientistsAbbey, SusanBaker, BrianColton, PatriciaDavis, CarolineGrace, SherryHall, PeterHeslegrave, Ron

Hodges, BrianIrvine, JaneMcVey, GailReid, GrahamRobinson, GailWoodside, Blake

Cellular & Molecular Biology

Senior ScientistsBackx, PeterBerger, StuartCardella, CarlCybulsky, MyronDick, JohnElsholtz, HarryFantus, GeorgeFish, EleanorGorczynski,ReginaldGotlieb, Avrum

Grant, DavidJohnston, WayneLangille, LowellLevy, GaryLiu, MingyaoPhillips, JamesRubin, BarryZacksenhaus,EldadZhang, Li

ScientistsCattral, MarkHusain, MansoorIrwin, DavidJin, Tianru

Kotra, LakshmiLam, TonyVolchuk, AllenWaddell, Thomas

AffiliateScientistsBelsham, DeniseBranch, DonaldClark, David

Cole, EdwardDrucker, DanielWen, Xiao-Yan

Clinical Decision-Making & HealthCare

Senior ScientistsBombardier,Claire

Jadad, AlexNaglie, Gary

Krembil Scientists

Brain, Imaging & Behaviour—Systems Neuroscience

Senior ScientistsBrotchie,JonathanChen, RobertDavis, KarenLozano, AndresHutchison,William

McAndrews, MaryPatMikulis, DaveSandor, PaulStrafella, Antonio

ScientistKucharczyk,Walter

AffiliateScientistsDe Nil, LucDostrovsky,Jonathan

Saint-Cyr, Jean

Fundamental Neurobiology

Senior ScientistsBroussard,DianneCarlen, PeterSkinner, Frances

Tymianski,MichaelWan, Qi

ScientistSugita, Shuzo

AffiliateScientistsEl-Beheiry,Hossam

Gaisano, HerbertZhang, Liang

Genetics & Development

Senior ScientistsBarr, CathyBremner, RodCardella, CarlEubanks, JamesFehlings, MichaelInman, RobertJongstra, Jan

Mills, LindaSchlichter, LyanneStanley, EliseTsui, FlorenceWither, JoanTator, Charles

ScientistMonnier, Philippe

Affiliate ScientistGuha, Abhijit

Health Care & Outcomes Research

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/statistics.php

1 of 3 4/21/2016 10:05 AM

Senior ScientistsDevins, GeraldGagliese, Lucia

Rodin, Gary

ScientistsEdelstein, KimHowell, Doris

Zimmermann,Camilla

AffiliateScientistsEsplen, MaryJane

Stewart, Donna

Signaling Biology

Senior ScientistsIkura, MitsuKhokha, RamaManoukian,Armen

Ohashi, Pamela

ScientistsCheung, PeterHakem, RazqallahJurisica, Igor

Koch, AnneOkada, HitoshiStambolic, VukVaziri, Homayoun

Stem Cells & DevelopmentalBiology

Senior ScientistsBarber, DwayneIscove, NormanKeller, GordonMak, TakMcCulloch, ErnestMedin, JeffreyMessner, Hans

Minden, MarkNeel, BenjaminPaige,ChristopherRottapel, RobertSchuh, Andre

OCI Clinical Research Unit

Members

Bayley, AndrewBell, BobBezjak, AndreaBoerner, ScottBrandwein,JosephBrierley, JamesBrown, DaleCatton, CharlesCatton, PamelaChang, HongChapman, WilliamChen, ChristineChen, XueyuChetty, RunjanCho, JohnChung, PeterCrook, JuanitaCroul, SidneyCrump, MichaelCummings,BernardDarling, GailDawson, Laurade Perrot, MarcDodge, JasonEasson,AlexandraElliott, MaryEvans, AndrewFeld, RonaldFinelli, Antonio

Laperriere,NormandLeighl, NatashaLevin, WildredLipa, JoanLipton, JeffreyManchul, LeeMason, WarrenMcCready, DavidMcLean, LindaMcLean, MichaelMenard, CynthiaMikhael, JosephMillar,Barbara-AnnMiller, NaomiMilosevic, MichaelNeligan, PeterO'Sullivan, BrianOza, AmitPaul, NarinderPayne, DavidPerez-Ordonez,BayardoPierre, AndrewQuirt, IanReece, DonnaRingash, JolieRosen, BarryRotstein, LorneShaw, PatriciaShepherd,

Daar, AbdallahEysenbach,Gunther

Singer, Peter

ScientistsAlibhai, ShabbirCheung, AngelaKrahn, Murray

Urbach, DavidWilson, Kumanan

AffiliateScientistsGoel, VivekLok, Charmaine

Tomlinson,George

CSRC MembersDaly, PaulJewett, Michael

Kapral, MoiraSinger, Lianne

Clinical Investigation & HumanPhysiology

Senior ScientistsAllard, JohaneBradley, DouglasCattran, DanielFloras, JohnKucharczyk,Walter

Lewis, GaryMiller, JudithOlivieri, NancySteiner, GeorgeWalmsley, Sharon

ScientistsPerkins, Bruce Wong, Florence

AffiliateScientistsDetsky, AllanDownar, EugeneEasty, AnthonyLogan, Alexander

Raboud, JanetReilly, RaymondSawka, AnnaZamel, Noe

CSRC MembersBril, VeraCameron,DouglasChan, CharlesChan, ChristopherChauhan, VijayCooper, RichardDjaiani, GeorgeFedorko, LudwikHarris, LouiseHerridge,MargaretIng, DouglasJassal, VanitaJohnston, Michael

Karkouti, KeyvanKarski, JacekMcCluskey, StuartMcRae, KarenParker, JohnRoss, HeatherSalit, IrvingSchwartz, LenSeidelin, PeterSherman, MorrisSiu, SamuelSlinger, Peter

Experimental Therapeutics

Senior ScientistsKeating, ArmandKelvin, DavidKeshavjee, ShafLi, Ren-KeLindsay, Thomas

Liu, Petervon Harsdorf,RudigerWeisel, Richard

Scientistsde Perrot, MarcNanthakumar,Kumar

Rao, VivekYau, Terrence

AffiliateScientistsFremes, StephenHwang, DavidMcCart, Andrea

McGilvray, IanMedin, Jeffrey

Genomic Medicine

Senior ScientistsBadley, ElizabethCarette, SimonCassidy, DavidDavis, AileenFortin, Paul

Gignac, MoniqueGladman, DafnaMahomed, NizarMailis, AngelaUrowitz, Murray

AffiliateScientistsCôté, PierreCott, CherylLineker, Sydney

Martino,Rosemary

Patient Based Clinical Research

Senior ScientistsDiamant, NicholasHeathcote, Jenny

Lang, AnthonyShapiro, ColinSharpe, James

Affiliate ScientistStephens, Robyn

Visual Science

Senior ScientistsFlanagan, JohnSteinbach, Martin

Trope, Graham

ScientistsHudson,Christopher

Wong, Agnes

AffiliateScientistsEizenman, MosheEthier, RossGallie, BrendaGonzalez, Esther

Irving, ElizabethWilkinson,Frances

Krembil Clinical Studies ResourceCentre (CRSC)

Members

Anastakis, DimitriBernstein, MarkBookman, ArthurBuys, YvonneChan, VincentChapman,KennethChung, FrancesDavey, Roderickdel Campo, JoseDevenyi, RobertEpstein, TrinaEscallon, JaimeEtlin, DavidEvans, MichaelFarb, RichardFung, KenGentili, FredGraham, BrentHawa, RaedIwanochko, MarkLam, Wai-ChingLam, RobertManninen, PirjoMassicotte, EricMcCartney, ColinMcGuire, GlennMcIntyre, RogerMelvin, KennethMiyasaki, JanisMontanera, Walter

Panisko, DanielParikh, SagarPeng, PhilipRadomski, SidneyRampersaud,YogaRootman, DavidRosen, CherylSaltzman-Benaiah, JenniferSeyone, ChanthShannon, PatrickShaw, JamesSilver, FrankSimons, MartinSinger, ShaunSlomovic, AllanSt George-Hyslop, PeterStanbrook,MatthewStubbs, BarbaraTarlo, SusanTerbrugge, KarelTu, KarenTumber, Paulvon Schroeder,HerbertVoon, ValerieWherrett, JohnWillinsky, Robert


2 of 3 4/21/2016 10:05 AM

Fleshner, NeilFyles, AnthonyGallinger, StevenGeddie, WilliamGhazarian, DannyGospodarowicz,MaryGreig, PaulGryfe, RobertHodgson, DavidIrish, JonathanJewett, MichaelJohnston, MichaelJones, JenniferKane, GabrielleKeating, ArmandKeshavjee, ShafKim, JohnKnox, JenniferKrzyzanowska,Monika

FrancesSimpson, RandSiu, LillianSturgeon, JeremySun, AlexanderSutherland,RobertSwallow, CarolSweet, JoanTkachuk, DouglasTrachtenberg,JohnTsang, Richardvan der Kwast,TheodorusWaddell, ThomasWaldron, JohnWarde, PadraigWarr, DavidWei, AliceWells, WoodrowWong, Rebecca

Senior ScientistsCole, DavidDowney, GregoryGeorge, SusanHogg, DavidKain, KevinLiles, Conrad

MacDonald, KellyPei, YorkSiminovitch,KatherineSole, Michael

ScientistOsborne, Lucy

AffiliateScientistsBoright, Andrew

Denomme,Gregory

TGRI Clinical Studies ResourceCentre (CSRC)

Members

Ali, MohamedBargman, JoanneBeattie, ScottBrister, StephanieColman, JackDavid, TironeDzavik, VladimirFenton, StanleyGardam, MichaelGirgrah, NigelGold, WayneGoldszmidt, EricGranton, JohnGrigoriadis,SophieHumar, AtulKachura, JohnKennedy, SidneyKeystone, EdwardLapinsky, StephenLilly, Leslie

Loke, JulianManktelow, RalphMerchant, NaeemNeary, Mary AnnO'Malley, MartinRajan, DheerajRakowski, HarryRalph-Edwards,AnthonyReznick, RichardRichardson,RobertRoberts, HeidiRoss, JohnStraus, SharonSutton, DavidSweet, JoanWilson, StephanieWolman, StephenYeo, Erik

Moro, ElenaNasmith, JamesOandasan, IvyOgilvie, RichardOgilvie-Harris,Darrell

Wong, DavidWong, JeanYogendran,SuntheralingamYu, Eric


3 of 3 4/21/2016 10:05 AM

New OCI Leadership AnnouncedJune 2006: Dr. Benjamin Neel—world-renowned cell signalingresearcher, Director of the Cancer Biology program at Boston'sBeth Israel Deaconess Medical Centre and Professor of Medicineat Harvard Medical School—was recruited as new Director ofOCI. Dr. Neel took up his position in January 2007.

New Regenerative Medicine Research Centre OpensDoorsOctober 2006: The opening of the new McEwen Centre forRegenerative Medicine was marked with a scientific symposiumof internationally-recognized stem cell researchers.Singer/philanthropist Sir Bob Geldof and lead donors Rob andCheryl McEwen led the celebrations.

Research Day a SuccessNovember 2006: More than 400 UHN researchers took part inUHN's annual Research Day. The event showcased 20 talks and130 poster presentations spanning the range of biomedicalinvestigation at UHN.

Researchers Set $49M Funding RecordNovember 2006: Drs. Pamela Catton, John Dick, Igor Jurisica,Kathy Siminovitch and Richard Weisel won $28 million in fundingfrom the Canada Foundation for Innovation (CFI), the highestamount ever awarded by the CFI to UHN in a single round. InApril 2007, the Ontario Research Fund made additional awards,bringing the total to $49M for these projects.

UHN's International Research Advisory Board VisitsDecember 2006: UHN hosted our International ResearchAdvisory Board members this month. During their visit, thegroup—Drs. Victor Dzau President & CEO, Duke UniversityHealth System), Ralph Steinman (Professor, RockefellerUniversity), Hans Wigzell (Professor, Karolinska Institute) andchair Philip Branton (Scientific Director, CIHR Institute of CancerResearch)—reviewed translational research initiatives at UHNand met with hospital and Foundation executives.

Dr.BenjaminNeel,recruitedfromHarvard,took up theOCIDirectorshipin January2007.

DonorRobertMcEwen(centre left)and Sir BobGeldof(centreright)sharedribbon-cuttingduties attheMcEwenCentre forRegenerativeMedicine'sgalaopening.

UHNresearchersmingle atUHNResearchDay.

A further$10Mdonationfrom leaddonors Roband CherylMcEwenraises theirtotalcommittmentto theirnamesakecentre to$20M.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/review.php

1 of 2 4/21/2016 10:06 AM

Regenerative Medicine Supported at McEwen Centrewith $10M GiftApril 2007: A new donation from Rob and Cheryl McEwen willsupport groundbreaking stem cell research through imagingfacilities, an embryonic stem cell laboratory, post-doctoralfellowships and programs designed to accelerate thedevelopment of scientific discoveries.

Development Acceleration Awardees AnnouncedSeptember 2007: Four UHN researchers—Drs. David Jaffray,Lothar Lilge, Li Zhang and Gang Zheng—were awardedDevelopment Acceleration Awards, a joint initiative betweenJohnson & Johnson and UHN. The award provides funding fordevelopment of imaging technolgoies in the context of neoplastic,cardiovascular, autoimmune, infectious, and/or neurologicaldisease.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/review.php

2 of 2 4/21/2016 10:06 AM

Leukemia: New Model Shows Human Disease Back toIts "Big Bang"Cancer researchers led by OCI's Dr. John Dick have developed amethod to convert normal human blood cells into "human" leukemiastem cells. The converted cells, when transplanted into special micethat permit the growth of human cells, can replicate the entiredisease process from the very moment it begins.

Explains Dr. Dick: "Most human leukemia research involves studyinga patient's diseased cells or a cell line grown from those cells.However, since cancer takes many months or years to develop, juststudying the cells at the end of the process does not let you knowwhat the series of changes were that caused the cells to becomeleukemic, and when they happened.

"With the method we developed, we have duplicated the naturalprocess every step of the way. It opens the pathway generally tounderstanding the process of how cancer begins."

Science. 2007 Apr 27; 316(5824):600-4. [ Abstract ]

Cancer: Anti-Aging Molecule May Help in Cancer FightA UHN research team led by Dr. Tak Mak discovered that a moleculethat helps extend the lifespan of flies and worms may also helpprotect against cancer.

FOXO3a, a member of a family of molecules that helps regulateanti-aging gene activity, was found to be capable of making cellsself-destruct via a process that relies on the tumour suppressormolecule p53.

The researchers found that FOXO3a has a paradoxical role: If it isturned on in the cell's nucleus, it stops p53 from working; however,outside of the nucleus, it can do the opposite-actively inducingp53-dependent programmed cell death.

"Interestingly, FOXO3a could trigger programmed cell death even insituations where p53 has lost its ability to work directly with DNA,"says Dr. Mak. "Pinpointing FOXO3a's involvement in programmedcell death gives researchers a new target for future anticancertherapies."

PNAS. 2006 Jun 13; 103(24):9051-6. Epub 2006 Jun 6. [ Abstract ]

Pancreatic Cancer: Combination Therapy OffersPromisesA new combination therapy has been demonstrated to prolongsurvival time in people with advanced pancreatic cancer, accordingto UHN researchers Dr. Malcolm Moore and Steven Gallinger. Thenew approach uses the compound erlotinib to target specificpathways overproduced in pancreatic cancer.

The two-year UHN-led National Cancer Institute of Canada ClinicalTrials Group study followed 569 patients treated with eithergemcitabine—the current treatment standard—alone or incombination with erlotinib. Patients who received the combination

The Ontario Cancer Institute is the research arm ofthe Princess Margaret Hospital.

OCI at a Glance

Research Space 389,000 sq ftPublications 553Total External Funding $102,854,000

Senior Scientists 49Scientists 20Affiliate Scientists 4CSRC/CRU Members 95Total Researchers 168

Fellows 201Graduate Students 169Total Trainees 370

Technical and Support Staff 461

OCI Council | Scientists | Clinical ResearchUnit | Full OCI Staff Listing

Research Council in Oncology

DirectorBenjamin Neel

Division HeadsApplied Molecular OncologyFei-Fei LiuBiophysics & BioimagingBrian WilsonCancer Genomics & ProteomicsLinda PennPsychosocial Oncology & Palliative CareGary Rodin

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/OCI.php

1 of 2 4/21/2016 10:06 AM

treatment experienced a significantly prolonged survival time andstabilization of disease.

"This combination therapy of gemcitabine plus erlotinib is the firstadvance in the treatment of pancreatic cancer in the past decade"says Dr. Moore. Erlotinib has been approved by the FDA and theEuropean Medicines Evaluation Agency for the treatment ofpancreatic cancer on the basis of this study and is under review byHealth Canada.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.[ Abstract ]

Leukemia: Fusion Protein Structure Reveals PotentialTargetDr. Mitsu Ikura and postdoctoral fellow Dr. Michael Plevin haverevealed the three-dimensional solution structure of the TAFHdomain-a domain critical for E protein interactions-of the AML1-ETOfusion protein using NMR spectroscopy.

AML1-ETO is generated by a translocation between chromosomes 8and 21, an event that occurs in up to 15% of acute myeloidleukemias (AML). AML1-ETO can silence E protein activation oftranscription factors that are involved in regulating cell growth,differentiation and apoptosis. By mutating AML1-ETO, this activity isreduced.

"Resolving the structure of protein domains and doing mutationalanalysis is key to understanding protein function," says Dr. Ikura."This domain of AML1-ETO showed a surprising similarity to anothercancer gene regulator Sin3. Our findings help us to obtain deeperinsights into leukemia and to design chemical inhibitors based onsimilarities and differences in their protein structures."

Proc. Natl. Acad. Sci. 2006. Jul 5; 103(27):10242-7. [ Abstract ]

Acute Myeloid Leukemia: Understanding FatigueA UHN study by researchers Drs. Shabbir Alibhai, GeorgeTomlinson, Joseph Brandwein, Mark Minden and Matthew Kowgierand Mr. Marc Leach is the first to investigate fatigue associated withacute myeloid leukemia (AML) in detail. AML—a cancer of theblood—is more common in adults 60 years and older and has asignificant effect on a patient's quality of life.

Patients were studied to characterize the prevalence and severity offatigue. Study authors show that fatigue was universal for all patientsthroughout the study regardless of treatment therapy with 98%having reported fatigue.

"Fatigue has a significant effect on a patient's quality of life, sogetting to the bottom is key," says Dr. Alibhai. "Our next steps are todig deeper into causes of fatigue, and whether chemotherapy orimproved disease control impact on fatigue and design interventionsto alleviate fatigue."

Leukemia. 2007. Apr; 21(4):845-8. [ Abstract ]

Signaling BiologyMitsu IkuraStem Cells & Developmental BiologyRobert RottapelClinical Research UnitPadraig Warde (Medical Site Director)

Clinical RepresentativesSylvia AsaMary GospodarowiczJonathan IrishMalcolm Moore

Centre for Research Education and TrainingDavid Rose

Vice President, ResearchChristopher Paige

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/OCI.php

2 of 2 4/21/2016 10:06 AM

Acute Respiratory Distress Syndrome: Study ShowsLong-Term Outcomes for SurvivorsA recent study by UHN researchers Drs. Angela Cheung , MargaretHerridge and George Tomlinson established that most survivors ofacute respiratory distress syndrome (ARDS) have a reduced health-related quality of life two years after being discharged from anintensive care facility. ARDS is a serious illness where fluidaccumulates in the lungs, which causes oxygen levels in the blood todrop to dangerously low levels.

The researchers followed 109 ARDS survivors for two years toexamine changes in the quality of life and associated healthcarecosts. They found that all health-related quality of life domains, otherthan emotional and mental health, were diminished compared tothose of the general population. However, most ARDS survivorsadapted to their situation and could live independently and return towork.

"Our findings suggest that future research efforts should concentrateon early intensive rehabilitation programs for ARDS," says Dr.Cheung. "These types of programs could help improve the long termoutcomes for ARDS survivors."

Am J Respir Crit Care Med. 2006 Sep 1; 174(5):538-44. Epub 2006Jun 6. [ Abstract ]

Heart Attack: Bone Marrow Molecule Signals Repair"Troops"UHN regenerative medicine researchers Drs. Shafie Fazel, MassimoCimini, Liwen Chen, Shuhong Li, Denis Angoulvant, Paul Fedak,Richard Weisel, Armand Keating and Ren-Ke Li have identified theSOS distress signal that mobilizes specific repair cells to the heartafter a heart attack.

C-kit, a molecule located on the surface of a subset of bone marrowcells, is turned on by the SOS signals sent by the damaged heart.C-kit binds to another molecule, activating c-kit to signal bonemarrow cells to home in on the heart to help stimulate new bloodvessel growth.

"Each year, 70,000 Canadians suffer from a heart attack and manyof them are left with crushing disabilities, mainly because the heartmuscle is not able to regenerate after a heart attack," says Dr. Li."This study identifies how the body naturally repairs the heart andprovides new potential therapies to stimulate cardiac regenerationand prevent heart failure in these patients."

J. Clin. Invest. 2006 Jul;116(7):1865-77. [ Abstract ]

Digestive System Diseases: Defining TreatmentCriteria for Swallowing DisorderPatients with the rare swallowing disorder achalasia are unable torelax the muscular ring that links the esophagus to the stomach.They experience difficulty swallowing and moving food from their

The Toronto General Research Institute is theresearch arm of the Toronto General Hospital.

TGRI at a Glance





TGRI Council | Scientists | Clinical StudiesResource Centre (CSRC) | Full TGRI StaffListing

Research Council

DirectorRichard Weisel

Division HeadsBehavioral Sciences & HealthGary RodinCell & Molecular BiologyEleanor FishClinical Decision-Making & Health CareClaire BombardierClinical Investigation & Human PhysiologyRichard Weisel (interim head)

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/TGH.php

1 of 3 4/21/2016 10:06 AM

mouth to their stomach through their esophagus-sometimes leadingto pain, regurgitation and dangerous weight loss.

There are two common surgical treatments for achalasia; however, itis not clear which treatment is less likely to result in the need forsubsequent interventions. To address the controversy, UHN healthservices researcher Dr. David Urbach performed a retrospectivestudy using data records from 1461 achalasia patients in Ontario.

"Our study shows that although both methods commonly result in theneed for subsequent intervention, less than 40% of patients treatedwith surgical dissection of the muscle had to be treated againcompared to more than 60% of patients treated by enlarging thecontracted opening using an air-filled balloon," says Dr. Urbach.

"Knowing that surgical dissection is slightly more efficient overall, wesuggest that doctors consider the patient's attitude toward surgicalprocedures and the desire to avoid further treatments when makingrecommendations."

JAMA. 2006 Nov 8;296(18):2227-33. [ Abstract ]

Heart Failure: Knowing the SignsA recent UHN-led study provides insight into the series of eventsinvolved in f heart failure, the fastest growing epidemic incardiovascular disease, the number one killer of Canadians. Drs.Peter Liu , Thomas Parker and Rama Khokha have determined theimportance of tumour necrosis factor alpha (TNFa)—usually involvedin many cell processes such as growth and survival—in regulatingcardiac repair and remodeling.

Using a mouse model, researchers compared the effects of pressureload on the left ventricle of the heart in the presence and absence ofTNFa. In the presence of TNFa, pressure-overloaded cardiac cellsare riddled with high levels of inflammatory proteins, leading to heartdilation, and the cells eventually succumb to TNF effects,contributing to cardiac dysfunction.

When TNFa was removed, adverse heart effects were reduced."Based on this effect, TNFa could be used to alert physicians whenheart repair processes threaten to deteriorate into heart failure," saysDr. Liu. "Even more exciting is its potential as a therapeutic tool inthe treatment of patients. We stumbled upon this finding quiteunexpectedly, and were surprised at its absolutely potent effect."

Circulation. 2007 Mar 20;115(11):1398-407. Epub 2007 Mar 12. [Abstract ]

Liver Transplant: Showing the Benefits of LiveDonationTGH has been a world leader in liver transplants involving livingdonors, and a recent study has proven the beneficial effects of thistreatment strategy. Living donation allows suitable recipients to avoidthe long organ waiting list but may represent unknown immediateand long-term health risks given that recipients receive only part of aliver.

To compare the risks of being on the list to those of receiving a livingdonation, UHN researchers Drs. David Grant, Gary Levy, Paul Greig,Ian McGilvray, Leslie Lilly, Nigel Girgrah and Mark Cattral reviewedsurvival rates and mortality of patients in the liver transplantprogram.

They found that patients who received a right-lobe of a liver from aliving donor had a higher survival rate post-transplant and reducedmortality on the waiting list than those who received a transplantfrom a deceased donor.

Says study leader Dr. Grant: "Live donor transplants significantlyshorten wait times and reduce the chance of death for those patientswho are on waiting lists. We have shown that we are able to help

Experimental TherapeuticsRichard Weisel (interim head)Genomic MedicineKatherine SiminovitchClinical Studies Resource CentreValerie Sales

Clinical RepresentativesGary LevyConrad LilesShaf KeshavjeeJohn Parker

Centre for Research Education and TrainingMingyao Liu

Site LeadMarnie Escaf

Research OperationsLisa Alcia


Standing Guests/Ex Officio MembersMedical Technology InnovationVivek RaoRegenerative MedicineTom WaddellTGRI Space CommitteeRen-Ke LiTGRI Appointments CommitteeShaf KeshavjeeMBRC Facilities Management CommitteeReginald GorczynskiFlow Cytometry FacilityLi ZhangMicroscopy FacilityLowell LangilleDiabetes Program and the Human PhysiologyDivisionGeorge Fantus


2 of 3 4/21/2016 10:06 AM

patients quicker and more effectively with live donation. Futurestudies will have longer follow-up times to more clearly understandthe advantages and disadvantages of living donors."

Am. J. Transplant. 2007 Apr; 7: 998-1002. [ Abstract ]


3 of 3 4/21/2016 10:06 AM

Arthritis: Predicting Probability of Joint ReplacementSurgeryThe need for improved patient education of people with arthritis ishighlighted in new work by UHN researcher Dr. Elizabeth Badley, Dr.Gillian Hawker (Women's College Hospital) and other Toronto-basedresearchers who looked at factors underlying a patient's decision toundergo joint replacement surgery.

In a prospective study, the researchers recorded information about3,307 seniors who were experiencing symptoms of arthritis in1995-1997. In 1999, the researchers followed up with 2,103respondents and found that—out of factors including education level,height, weight, socioeconomic factors, employment and livingarrangements—the most important determining factor waswillingness to have the surgery.

"Joint replacement surgery is a cost-effective treatment fordebilitating arthritis of the hip and knee, and disparities in rates ofsurgery are troubling. Willingness to consider surgery as a treatmentoption results from improved patient understanding. This underlinesthe fact that we need to continue to develop and implementstrategies to educate the community about arthritis and replacementsurgery outcomes," says Dr. Badley.

Arthritis Rheum. 2006 Oct;54(10):3212-20. [ Abstract ]

Brain Injury: Research at the Forefront of NewTherapiesA new UHN finding is the first step towards developing new multi-pronged strategies for traumatic brain injury (TBI).

Damage to a brain cell sets off a cascade of internal and externalevents that combine to create a toxic environment, killingneighbouring cells over a large area. While neuroscientists arestarting to understand this complex mechanism, treatments whichaddress a single component of the cascade have provenunsuccessful in clinical trials. Thus researchers are moving to amulti-pronged paradigm to address two or more componentssimultaneously.

A pioneering study led by Dr. Michael Tymianski and graduatestudent Anthony Lau has shown that due to the effects of a lethalby-product of cell damage called peroxynitrate, TBI therapy shouldinclude both anti-oxidant and anti-apoptotic compounds.

"If we can use molecular approaches to prevent the oxidizingprocess, which forms hazardous reactive oxygen molecules in thebrain, and the apoptosis process, which leads to programmed celldeath, we may be able to reduce cell death in these injuries,"explains Dr. Tymianski.

J Neurosci. 2006 Nov 8;26(45):11540-53. [ Abstract ]

Degenerative Disc Disease: Notochord Cells Help toRegenerate Disc CartilageDrs. Mark Erwin and Robert Inman have discovered that notochord

The Krembil Research Institute is the researcharm of the Toronto Western Hospital.

Krembil at a Glance





Krembil Council | Scientists | Clinical StudiesResource Centre (CRSC) | Full Krembil StaffListing

Research Council

DirectorPeter St George-Hyslop

Division HeadsGenetics & DevelopmentRod BremnerFundamental NeurobiologyPeter CarlenBrain, Imaging & Behaviour - SystemsNeuroscienceKaren DavisVisual Science

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/TWH.php

1 of 2 4/21/2016 10:07 AM

cells-which are primitive organizing cells of the developing embryo-release a factor called connective tissue growth factor (CTGF) thatmay be responsible for providing certain strains of dogs with theirremarkable resistance to degenerative disc disease.

Degenerative disc disease is one of today's most common andcostly medical conditions, marked by a progressive loss of discheight, mechanical properties and tissue degradation. However, inresistant dog strains it does not occur or occurs much later in life.

To find out why resistant dogs are protected, the UHN team obtainednotochord cells from the discs of the dogs and determined theidentity of some of the proteins secreted by these cells. They thenused the proteins secreted by these cells to determine what disc cellgenes are turned on by these notochord cells.

"Our results suggest that certain breeds of dogs are protectedagainst this disease because their discs contain an abundance ofnotochord cells that are releasing CTGF," says Dr. Inman. "Thisresearch will likely provide the groundwork to regenerate disccartilage for patient treatment in the future."

Arthritis Rheum. 2006 Dec;54(12):3859-67. [ Abstract ]

Spinal Cord Injury: Rebuilding from the Ground UpA team led by Krembil researcher Dr. Michael Fehlings hasdemonstrated a new way to reconstruct an essential element innerve function in the spinal cord in a paper jointly co-first authored byDrs. Eftekhar Eftekharpour and Soheila Karimi.

A tissue called myelin functions as an insulating casing around nervefibers and takes part in conducting signals from the brain to the restof the body. After transplanting specific neural precursor cells(aNPCs) from the brain of adult transgenic mice into the spinal cordsof mice which lack myelin, investigators were able to generateoligodendrocytes—the building blocks of myelin—which traveleddown the spinal cord and formed mature myelin.

"This is a major step forward in spinal cord injury research," says Dr.Fehlings. "The ability to restore the myelin insulation is a keycomponent of a therapeutic strategy, and our study is the first toshow this exciting result. Our future work will focus on generatingneural precursor cells from alternative sources including embryonicstem cells and in applying this technology is concert with tissueengineering approaches to repair chronic spinal cord injury."

J Neurosci. Mar 28, 27(13): 3416-28. [ Abstract ]

Martin SteinbachHealth Care & Outcomes ResearchElizabeth BadleyPatient Based Clinical ResearchJenny Heathcote

Clinical RepresentativesMichael FehlingsRobert InmanNizar MahomedMartin Steinbach

Centre for Research Education and TrainingFrances Skinner

Site LeadKathy Sabo

Research OperationsLisa Alcia


University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/TWH.php

2 of 2 4/21/2016 10:07 AM

In 2006/07, UHN researchers were recognized by peers aroundthe world for their achievements:

Dr. Frances ShepherdO. Harold Warwick Prize for significantly impacting cancer controlin Canada, awarded by the National Cancer Institute of Canada

Dr. Pamela OhashiElected to the Royal Society of Canada

Dr. Robert InmanJonas Salk Award for making a new and outstanding contributionto prevent, alleviate or eliminate a physical disability, awarded bythe Ontario March of Dimes

Drs. Vivek Rao and Aaron SchimmerCanada 's "Top 40 Under 40"

Drs. Conrad Liles, Gordon Keller, Benjamin Neel,Eleanor Fish and Linda PennCanada Research Chairs, Tier I

Drs. Igor Jurisica, Thomas Kislinger, Shuzo Sugitaand Elisabeth TillierCanada Research Chairs, Tier II

Dr. Brian WilsonLifetime Achievement Award, Optical Imaging Workshop, NationalInstitutes of Health (U.S.)

Dr. George SteinerNamed a Distinguished Fellow of the International AtherosclerosisSociety

Dr. Peter St George-HyslopHoward Hughes Medical Institute International Research ScholarAward

Drs. John Dick, Tak Mak and Peter StGeorge-HyslopUHN researchers swept three of the four inauguralPremier's Summit Awards awarded at a galaceremony in April 2007. Drs. John Dick, Tak Makand Peter St George-Hyslop will each receive$2,500,000 towards new research projects

Drs. Brenda Gallie, Ernest McCullochand James TillThree UHN researchers were invested into theOrder of Ontario in 2006. Drs. Brenda Gallie,Ernest McCulloch and James Till received theprovince's highest offical honour for excellenceand outstanding contribution to society in Ontarioand around the world.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/honour.php

1 of 2 4/21/2016 10:07 AM

Support for Groundbreaking Research across UHN'sPrograms

2006/07 marked a record year for UHN in CFI grant fundingearned. A round earned five UHN research teams a collectivetotal of $21.4M in new infrastructure funding and $6.4M inoperating funding—a UHN record. Later this year, projects wereawarded an additional $21.4M through the Ontario ResearchInfrastructure program, resulting in a funding total of over $49Mfor these five projects.

The awards fund a variety of projects across UHN's priorityresearch areas.

Regenerative Medicine Scores Twin WinsRegenerative medicine is one of UHN's research priorityplatforms, and one of its flagship programs is the newRegenerative Medicine (REMEDI) Project, recently funded byCFI, which provided $7.2M in funding. This new centre willcomprise cutting-edge multi-imaging infrastructure with multi-dimensional visualization. Led by Dr. Richard Weisel, this projectdrives regenerative medicine research to clinical applications for avariety of diseases.

"REMEDI is an innovative approach to regenerative medicine,"Dr. Weisel explains. "It is a multidisciplinary initiative, which willenable innovative and customized research technologies tofacilitate investigations intended to provide new regenerativetherapies including: labeling, imaging, visualization and guideddelivery. The project will unite experts from numerous fields:engineers, computer scientists, molecular biologists and cliniciansto find unique new treatments to restore function to diseasedorgans. Ultimately, the vision of regenerative medicine researchwill be to provide cutting-edge therapeutic tools to improve thehealth of Canadians."

Another project within the regenerative medicine platform is Dr.John Dick's new Cancer Stem Cell Centre. This project, whichsecured over $4M in CFI funding, focuses on developing cancerstem cell therapies. It consists of several core activities includinglive cell banking, xenotransplanting, flow cytometry, highthroughput screening and imaging. As a result, it will enablecancer stem cell scientists to develop improved predictivediagnostic and prognostic tests, as well as pursue new cancertherapies.

Genomics, Systems Biology and SurvivorshipResearch Also WinnersAlso receiving CFI funding this year was Dr. KatherineSiminovitch's Disease Genomics: Reduction to Practice. This$4.8M proposal, aligned with UHN research's priority platform inGenes, Proteins and People, builds on UHN's Clinical GenomicsCentre, a state-of-the-art genomics and proteomics technologyplatform. The development of profiling tools and new medicationsare among the outcomes that ultimately lead to improved patientmanagement.

Dr. Richard Weisel, head of the REMEDI Project,demonstrates the computer visualization lab.

CFI Grants Awarded at UHN, 2007

Regenerative Medicine (REMEDI)ProjectDr. Richard Weisel

$7.2M

Disease Genomics: Reduction toPracticeDr. Katherine Siminovitch

$4.8M

Cancer Stem Cell CentreDr. John Dick

$4.3M

Comprehensive Systems BiologyApproach to Profiling and Modelingof CancerDr. Igor Jurisica

$4.0M

Electronic Living Laboratory forInterdisciplinary CancerSurvivorship ResearchDr. Pamela Catton

$1.2M

Total Funding $21.5M

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/CFIgrants.php

1 of 2 4/21/2016 10:07 AM

Dr. Igor Jurisica's Comprehensive Systems Biology Approach toProfiling and Modeling of Cancer received over $4M from CFI.This project, which enables the interdisciplinary, integrated andcollaborative profiling and modeling of cancer, is aligned with twoof UHN research's priority platforms—Genes, Proteins andPeople, and Health Informatics. Through this endeavour,researchers aim to understand cancer at a molecular level, whichcan lead to a number of benefits: improvement in the quality andcost of cancer diagnosis and treatment via intelligent molecularmedicine, the identification of novel and more specifically targeteddrugs, as well as increased efficiency of current therapies.

The Electronic Living Laboratory for Interdisciplinary CancerSurvivorship Research, an innovative new approach to researchin cancer, was awarded $1.2M in CFI funding. Headed by Dr.Pamela Catton, this initiative leverages the intellectual capital ofcancer survivors to examine new approaches to predict, preventand manage long-term adverse effects of cancer and itstreatment. Through examining social networks and competencybuilding, distributed models of care, health knowledge transferand sustainability, innovative research into chronic disease healthcare delivery—using cancer survivorship as a model—will beperformed.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/CFIgrants.php

2 of 2 4/21/2016 10:07 AM

Leading the Way in Regenerative Medicine

Last year, stem cell research took a large step forward with theopening of the McEwen Centre for Regenerative Medicine atUHN.

UHN Celebrates with Scientific SymposiumMore than 300 members of the scientific community attended thescientific symposium which launched the festivities. CentreDirector Dr. Gordon Keller, an internationally acclaimed embryonicstem cell scientist and co-chair of the symposium, was alsoofficially introduced to the Toronto research community.

World-renowned researchers—including Drs. John Dick , Rudigervon Harsdorf, Thomas Waddell, Michael Fehlings, Janet Rossant,Derek van der Kooy, and keynote speaker Dr. George Daley—described stem cells and their significance to various biomedicalfields, showcasing their unique ability to change the face ofmedicine and health on numerous fronts.

Following the symposium, a tour of the facilities—with musicianSir Bob Geldof among the attendees—continued the celebration.The event ended with a gala reception and dinner hosted byphilanthropists and lead donors Robert and Cheryl McEwen.

Centre Focuses on Research & CommercializationAs a key component of UHN's regenerative medicine researchpriority platform, the Centre focuses on three specific areas:repair and regeneration, origins and models of disease and newtools for discovery. Heart disease, diabetes, blood cell disordersand spinal cord and neurodegenerative diseases are the corefields of investigation, while research in other diseases, includingthose of the lungs, as well as muscular/skeletal andgastro/intestinal conditions, will also be pursued.

In addition to establishing the Centre, which is located on the 8thfloor of the Toronto Medical Discovery Tower , funding will allowregenerative medicine researchers from across UHN and acrossToronto to attract new trainees through new postdoctoralfellowships as well as to pursue new modes of commercializationvia enhanced support for this program.

"This is truly an exciting opportunity," says Dr. Keller. "There is anenormous pool of talented regenerative medicine researchers inToronto. My goal as the Director of the McEwen Centre forRegenerative Medicine is to create an environment that will fostercross-disciplinary interactions and encourage investigators towork synergistically towards the development of innovativeregenerative medicine approaches."

New Centre Director Dr. Gordon Keller wasrecruited to UHN from Mt. Sinai Hospital,New York.

Keynote speaker Dr. George Daley (left) wasintroduced by McEwen member Dr. JohnDick.

Dignitaries and McEwen members celebratedthe opening on-stage.

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/McEwen.php

1 of 2 4/21/2016 10:07 AM

UHN Core Research Funding(in thousands of dollars)

Princess Margaret Hospital Foundation 15,341

Toronto General & Western Hospital Foundation 2,502

Arthritis & Autoimmunity Research Centre Foundation 1,259

Ministry of Health & Long Term Care 2,850

Recoveries 7,652

Investment income 2,814

Other 13,213

TOTAL 45,631

UHN External Research Funding(in thousands of dollars)

Operating Grants 74,719

Infrastructure / Maintenance Awards 24,339

Clinical Studies 17,997

Other 9,759

Career / Traineeship Awards 7,642

Corporate Contracts 7,225

TOTAL 141,681

External Agencies Funding UHN Research

A-C D-L M-O P-Z

Full Listing

Abbott LaboratoriesAdvanced Cardiovascular SystemsAdvanced Neuromodulation SystemsAegera TherapeuticsAgouron PharmaAlbert Einstein College of Medicine of YeshivaUniversityAlberta Heritage Foundation for MedicalResearchAlexion PharmaceuticalsAllerganAmerican Association for Thoracic SurgeryAmerican Association of Neurological SurgeonsAmerican Cytoscope MakersAmerican Heart AssociationAmerican Society of Plastic Surgeons' PlasticSurgery Educational FoundationAmerican Society of Regional Anesthesia andPain MedicineAmgenAmorfix Life SciencesAmyotrophic Lateral Sclerosis Society of CanadaAOSpine North AmericaArgiNOx PharmaceuticalsArgonne National LaboratoryArgos TherapeuticsArius ResearchArthritis Community Research & Evaluation UnitArthritis SocietyAsprevaAstellas Pharma CanadaAstra PharmaAstraZeneca CanadaAtheroGenicsAtukaAventis PasteurBanting and Best Diabetes CentreBausch and LombBaxter HealthcareBaycrestBayerBeckman CoulterBell CanadaBioAxone TherapeuticBioChem TherapeuticBioMimetic TherapeuticsBoehringer Ingelheim

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/funding.php

1 of 2 4/21/2016 10:08 AM

Major Sources of External Funding(in thousands of dollars)

Canadian Institutes of Health Research 24,653

Canada Foundation for Innovation/OIT 22,318

National Cancer Institute of Canada 7,275

National Institutes of Health (US) 6,843

Ontario Institute for Cancer Research 4,581

Heart and Stroke Foundations 3,973

Ontario Genomics Institute 2,726

Canada Research Chairs Program 2,556

All figures represent fiscal year 2006/07 and include OntarioCancer Institute (Princess Margaret Hospital); Toronto GeneralResearch Institute (Toronto General Hospital); and KrembilResearch Institute (Toronto Western Hospital).

These figures have been provided by UHN Research FinancialServices and Research Grant and Contract Services. Thesefigures have not been audited. However, they have been includedin the overall UHN statements and, as a result, have beensubjected to audit procedures deemed appropriate by auditors inorder to determine their overall reasonableness.

Boston ScientificBristol-Myers SquibbBurroughs Wellcome FundCAD SciencesCalouste Gulbenkian FoundationCanada Foundation for InnovationCanada Research Chairs ProgramCanadian Arthritis NetworkCanadian Association of GastroenterologyCanadian Breast Cancer FoundationCanadian Breast Cancer Research AllianceCanadian Breast Cancer Research InitiativeCanadian Coordinating Office for HealthTechnology AssessmentCanadian Cystic Fibrosis FoundationCanadian Diabetes AssociationCanadian Health Services Research FoundationCanadian Institutes of Health ResearchCanadian Liver FoundationCanadian Neuromodulation SocietyCanadian Patient Safety InstituteCanadian Urologic Oncology GroupCancer Care OntarioCancer Research InstituteCancer Research SocietyCaprion ProteomicsCelgeneCell GenesysCentocorCentre for Addiction and Mental HealthCentrum FoundationCeraPedicsChemBridge Research LaboratoriesChironChristopher Reeve Paralysis FoundationCleveland Clinic Lerner College of Medicine ofCase Western Reserve UniversityCraig H. Neilsen FoundationCSLCV TherapeuticsCyanamidCyclacel Pharmaceuticals

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/funding.php

2 of 2 4/21/2016 10:08 AM

Ontario Cancer Institute

Animal Care Committee

Richard Hill (Co-chair)Norman Iscove (Co-chair)Beryl Nash (CommunityRepresentative)Monica BaileyShelley BelfordLih Ling ChungJean Flanagan

Tuula KalliomakiMelissa MaddenBadru MolooHitoshi OkadaChristine QuarringtonJeffrey SiewerdsenElisabeth Tillier

Research Appointments Committee

Benjamin Neel (Chair)Mitsu IkuraNorman IscoveDavid JaffrayFei-Fei Liu

Mark MindenChristopher PaigeGary RodinRobert Rottapel

Common Equipment Committee

Gilbert Privé (Chair)Dwayne BarberPeter CheungTony GoncalvesRichard Hill

Janet MaIan McDermottMalcolm SmithAaron SchimmerAlex Vitkin

Clinical Research Unit Executive

James BrierleyDarlene DaleGerald DevinsMary GospodarowiczJonathan IrishArmand KeatingMichael Milosevic

Martin O'MalleyTony PanzarellaMichael ReedijkSusanna SellmannPatricia ShawFrances ShepherdPadraig Warde

Clinical Research Implementation Committee

Andrea AfinecLidia CasciaroHeather ColeDarlene DaleJeffrey DoiVicky GillmanDebbie Havill

Karen HerseyJennifer HornbyAzizunissa IrumnazJane NagaiMaria OldfieldLarissa PotaninaLinda Purushuttam

Data Safety Monitoring Board

Jolie Ringash (Chair)Mark Minden (Co-chair)Dale BrownJennifer Petronis

Di WangLisa WangDavid Warr

Ex Officio MembersMonica PhillipsLarissa Potanina

Susanna Sellmann

Toronto General Research Institute

Clinical Research Advisory Committee

Biosafety Committee

Jim Brunton (Chair)Eric BaillieRichard BilanTuyet DiepAmbrosio DiMagibaZahir HirjiIan McDermottJeffrey Medin

Badru MolooTim SavageJohn ShannonJuliet SheldonAaron SchimmerSuzanne TrudelJacquie TumakJoan Wither

Radionuclide Safety Committee

Ian McDermott(Co-chair)Frank Tourneur(Co-chair)Neil AmosJonathan BrotchieRon Burke>Lisa ColangeloMarc Freeman

Judy GabrysAaron HendlerRay IlsonNorman IscoveScott JarrettEd KasprzakAllen VolchukMing-Der Yu

Research Ethics Board (A)

Ronald Heslegrave(Chair)Alan BaroletDerek CathcartSteven FriedmanCindy HeinzKaren McRaeKatherine RoposaHeather SampsonRon Seto

Elizabeth SlossCatherine TanseyKatherine TsangDi WangDiane WatsonLinda WrightNoe ZamelAlison Miculan(Non-voting member)

Research Ethics Board (B)

Ronald Heslegrave(Chair)Kyle AnsteyCarol BargmanRuth Anne BaronDavid BarthWilfred Cassar-DemajoPaul DalyMariel EscoverLudwik FedorkoJin Huh

Margaret HumeWilliam HutchisonPatricia LombardRoger McIntyreVaska MicevskiJudith MillerDheeraj RajanAlex Kerr (Non-votingmember)Lorraine Baladjay(Non-voting member)

Research Ethics Board (C)

Ronald Heslegrave(Chair)Anthony BradeCarol Ann BuckleyPavel Crystal

Naomi MillerJane NagaiAndre SchuhDonald ShortKittie Tomson

University Health Network Research Report 2007 http://www.uhnres.utoronto.ca/RR/committees.php

1 of 3 4/21/2016 10:08 AM

Richard Weisel (Chair)Johane AllardScott BeattieClaire BombardierDouglas BradleyDaniel CattranGerald DevinsAlastair FlintJohn FlorasDavid GrantJohn GrantonLea HarringtonAllan KaplanKeyvan Karkouti

Sidney KennedyMurray KrahnDouglas LeeGary LevyJudith MillerKumar NanthakumarJohn ParkerYork PeiDheeraj RajanHeather RossValerie SalesAnna SawkaDavid Urbach

Basic Research Advisory Committee

Richard Weisel (Chair)Mark CattralMyron CybulskyEleanor FishReginald GorczynskiAvrum GotliebRudiger von HarsdorfMansoor HusainGordon KellerDavid KelvinShaf KeshavjeeLowell Langille

Gary LevyRen-Ke LiMingyao LiuPeter LiuIan McGilvrayVivek RaoAllen VolchukThomas WaddellRichard WeiselTerrence YauLi Zhang


Shaf Keshavjee (Chair)Eleanor FishMansoor HusainConrad LilesMingyao Liu

Christopher PaigeGary RodinRichard WeiselLi Zhang

MBRC Facilities Management Committee

Reginald Gorczynski (Chair)Fayez DawoodMichelle DeetonTuyet DiepDavid Irwin

Ming Fung LiuIan McDermottChristine QuarringtonAlan Rosenthal

Krembil Research Institute


Elizabeth BadleyStuart BergerRod BremnerPeter CarlenKaren Davis

Jenny HeathcotePeter St George-HyslopAndres LozanoMartin Steinbach

Shared Equipment Committee

Shelley BelfordRod BremnerJonathan BrotchiePeter St George-HyslopJan Jongstra

Ian McDermottPhilippe MonnierJuliet SheldonMartin SteinbachShuzo Sugita

Space Committee

James Eubanks (Chair)Rod BremnerMonique Gignac

Ian McDermottPeter St George-HyslopFrank Vidic

Trainee Affairs Committee

William Hutchison (PIRepresentative)Joan Wither (PIRepresentative)Joan ForderDarrell HauflerRaquel Heskin

Minnie KimChristina LohFrances SkinnerHong SunHeather Titley

Laura DawsonAurora De BorjaJeffrey DoiMichele HenryAzizunissa IrumnazWey LeongGina LockwoodHelen MackayWarren MasonMichael McLean

John WaldronAlice WeiWoody WellsKaren YeePaola Cubillos-Rizo(Non-voting member)Larissa Potanina(Non-voting member)

Research Information Systems User Group

Norman Iscove (Chair)Stuart BergerChip CampbellAngela CheungPeter CheungKaren DavisJoe de LeónDavid Eagan

Brenda GallieThomas GoldthorpeJacqueline JordanIgor JurisicaThomas KislingerKatherine RoposaNeil Winegarden

Cancer Registry and Data Access Committee

James Brierley(Co-chair)Darlene Dale (Co-chair)Alexandra EassonDavid Goldstein

Vikas GuptaDavid HodgsonMonika KrzyzanowskaMarta WasTony Panzarella

Human Tissue Committee

Ronald Heslegrave(Chair)Carol CheungPaola Cubillos-RizoMichele Henry

Richard HillMichael JohnstonPatricia ShawJeremy SquireMing-Sound Tsao

Ad Hoc MembersSylvia AsaDenis BaileyScott BoernerJagdish ButanyJames BrierleyWilliam ChapmanRunjan ChettySidney CroulMichael CrumpShereen EzzatNeil FleshnerAnthony FylesRalph GilbertMaha Guindi

Rita KandelNormand LaperriereDavid McCreadyMark MindenBrian O'SullivanBayardo Perez-OrdonezFrances ShepherdRand SimpsonJoan SweetMing-Sound TsaoErik YeoBruce YoungsonYeni Yucel

CREdiT Advisory Committee

Karla BadgerCathy BarrJoan ForderRichard HillChristina LohMingyao LiuTrevor McKeeBenjamin Neel

Maral OuzounianChristopher PaigeDavid RoseMasaaki SatoFrances SkinnerDavid UrbachRichard Weisel


2 of 3 4/21/2016 10:08 AM

Toronto General and Krembil Research Institutes

Animal Care Committee

Jeffrey Medin (Chair)Jan Jongstra (Vice-chair)Kathleen Cook (CommunityRepresentative)Shelley BelfordLih Ling ChungHossam El-BeheiryCarole Galligan

Lothar LilgeMelissa MaddenAndrea McCartLinda MillsPhilippe MonnierBadru MolooChristine QuarringtonJeff Tong


3 of 3 4/21/2016 10:08 AM

university health network research report 2007

Documents